transplantation rejection
Recently Published Documents


TOTAL DOCUMENTS

89
(FIVE YEARS 25)

H-INDEX

11
(FIVE YEARS 2)

2021 ◽  
Vol 26 (01) ◽  

For the month of January 2022, APBN looks at some discoveries and innovation in pharmacology. In Features, Dr Harish Dave, Co-Founder and Chief Medical Officer of AUM Biosciences, discusses today's shifting paradigm in oncology drug development towards highly selective, minimally toxic, and patient-centric treatments, while Jade Pallett, Chief Technology Officer for Zoono UK & Europe, sheds light on how antimicrobial coatings outdo traditional methods of disinfection. Then, we have A/Prof Alexandra Sharland, Dr Nicole Mifsud, and Eric Son to elucidate how understanding antigen-specificity of host T cells can reduce organ transplantation rejection. Finally, in Spotlights, we have two interviews – one where we speak to Mr Willson Deng, CEO of Arcstone, on the role of digital technology in supporting MedTech manufacturing, and the other with Liu Qun, Head of IQVIA, China, where we learn more about the Chinese biopharmaceutical market.


2021 ◽  
Vol 12 ◽  
Author(s):  
Jinwen Lin ◽  
Ying Chen ◽  
Huijuan Zhu ◽  
Kai Cheng ◽  
Huiping Wang ◽  
...  

Chronic rejection of the renal allograft remains a major cause of graft loss. Here, we demonstrated that the remodeling of lymphatic vessels (LVs) after their broken during transplantation contributes to the antigen presenting and lymph nodes activating. Our studies observed a rebuilt of interrupted lymph draining one week after mouse kidney transplantation, involving preexisting lymphatic endothelial cells (LECs) from both the donor and recipient. These expanding LVs also release C-C chemokine ligand 21 (CCL21) and recruit CCR7+ cells, mainly dendritic cells (DCs), toward lymph nodes and spleen, evoking the adaptive response. This rejection could be relieved by LYVE-1 specific LVs knockout or CCR7 migration inhibition in mouse model. Moreover, in retrospective analysis, posttransplant patients exhibiting higher area density of LVs presented with lower eGFR, severe serum creatinine and proteinuria, and greater interstitial fibrosis. These results reveal a rebuilt pathway for alloantigen trafficking and lymphocytes activation, providing strategies to alleviate chronic transplantation rejection.


2021 ◽  
Vol 105 (12S1) ◽  
pp. S31-S31
Author(s):  
Pedro Ventura-Aguiar ◽  
Maria Jose Ramirez-Bajo ◽  
Navchetan Kaur ◽  
Zachary Demko ◽  
Jordi Rovira ◽  
...  

Cornea ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Edward H. Lee ◽  
Jennifer Y. Li

Author(s):  
Jiang Bian ◽  
Ting Wang ◽  
Jijun Sun ◽  
Xiaozhen He ◽  
Zhijiao Wu ◽  
...  

2021 ◽  
Author(s):  
Shipeng Li ◽  
Guangpeng Zhou ◽  
Jie Sun ◽  
Bin Cui ◽  
Haiming Zhang ◽  
...  

Abstract It is still unclear whether there are differences in the types and functional status of immune cells in different areas of the liver lobules after liver transplantation rejection. The composition of infiltrating T cells in liver allografts during liver transplantation rejection is unclear and difficult to visualize on the same biopsy slide. We used multiplex immunofluorescence assays to study the spatial distribution of various types of infiltrating T cells in different areas of the liver lobules after liver transplantation. In the same area of the hepatic lobules, the percentage of CD4 + T cells, CD8 + T cells and regulatory T cells (Tregs) in the acute rejection group was higher than that in the nonacute rejection and normal groups. Within all three groups, the percentage of CD4 + T cells, CD8 + T cells and Tregs from the periportal to perivenous zones was increased first and then decreased. The percentage of CD8 + T cells increased gradually from the periportal to perivenous zones, the percentage of CD8 + T cells in perivenous zone was higher than in the transitional and periportal zones in the rejection group. In conclusion, the percentage of CD8 + T cells in different regions of liver lobules is closely related to rejection level after liver transplantation. Acute liver transplantation rejection may occur when the percentage of CD8 + T cells in the perivenous zone increases. Although the percentage of regional CD4 + T could not reflect the rejection level, but the number of CD4 + and CD8 + T cells in different regions was closely related to the rejection level.


2021 ◽  
Author(s):  
Huiwen Tian ◽  
Shumei Lin ◽  
Jing Wu ◽  
Ming Ma ◽  
Jian Yu ◽  
...  

Abstract Corneal transplantation rejection remains a major threat to the success rate in high-risk patients. Given the many side effects presented by traditional immunosuppressants, there is an urgency to clarify the mechanism of corneal transplantation rejection and to identify new therapeutic targets. Kaempferol is a natural flavonoid that has been proven in various studies to possess anti-inflammatory, antioxidant, anticancer, and neuroprotective properties. However, the relationship between kaempferol and corneal transplantation remains largely unexplored. To address this, both in vivo and in vitro, we established a model of corneal allograft transplantation in Wistar rats and an LPS-induced inflammatory model in THP-1 derived human macrophages. In the transplantation experiments, we observed an enhancement in the NLRP3 / IL-1 β axis and in M1 macrophage polarization post-operation. In groups to which kaempferol intraperitoneal injections were administered, this response was effectively reduced. However, the effect of kaempferol was reversed after the application of autophagy inhibitors. Similarly, in the inflammatory model, we found that different concentrations of kaempferol can reduce the LPS-induced M1 polarization and NLRP3 inflammasome activation. Moreover, we confirmed that kaempferol induced autophagy and that autophagy inhibitors reversed the effect in macrophages. In conclusion, we found that kaempferol can inhibit the activation of the NLRP3 inflammasomes by inducing autophagy, thus inhibiting macrophage polarization, and ultimately alleviating corneal transplantation rejection. Thus, our study suggests that kaempferol could be used as a potential therapeutic agent in the treatment of allograft rejection.


Sign in / Sign up

Export Citation Format

Share Document